CN-122010917-A - Compound for relieving cell damage caused by heavy ion radiation, medicine and application

Abstract

The invention relates to the technical field of biological medicines, and particularly provides a medicine for relieving cell damage caused by heavy ion radiation and application thereof. The medicine can remarkably improve the survival rate of cell clone under the condition of carbon ion radiation, inhibit the occurrence of necrotic apoptosis and weaken inflammation related transcription reaction caused by the radiation. The invention is verified by multi-level experiments such as clone formation experiments, protein level detection, transmission electron microscope observation, transcriptome analysis and the like, and the pharmaceutical composition can specifically improve the survival state of cells after carbon ion irradiation, and has no obvious protection effect on X-ray irradiation. The invention provides a new pharmaceutical scheme for the related protection and complication intervention of heavy ion radiotherapy, and has important application prospect.

Inventors

• SU FENGTAO
• SUN JUN
• SHAO CHUNLIN
• KONG LIN
• ZHANG QING
• WU KAILIANG
• LOU XIAOKUN
• LI CHONG
• LIU XUEYANG
• XIAO MEI

Assignees

• 上海市质子重离子医院有限公司

Dates

Publication Date

20260512

Application Date

20251212

Claims (7)

1. 1. A compound for alleviating cell damage caused by heavy ion radiation, wherein the compound is Necrosulfonamide, and has a structure shown in formula I:
2. 2. a medicament for alleviating cellular damage caused by heavy ion radiation, comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
3. 3. Use of a compound according to claim 1 or a medicament according to claim 2 for the manufacture of a medicament for alleviating cellular damage caused by heavy ion radiation.
4. 4. The use according to claim 3, wherein the use in the medicament for alleviating cell damage caused by heavy ion radiation is selected from any one or more of cell damage, tissue inflammatory response, and treatment-related adverse reactions caused during heavy ion radiation therapy.
5. 5. The use according to claim 4, wherein the method for alleviating cell damage caused during heavy ion radiation therapy is to increase cell viability and/or inhibit necrotic apoptosis.
6. 6. The use of claim 4, wherein the alleviation of tissue inflammatory response is attenuation of inflammation-associated transcriptional signals.
7. 7. Use according to claim 3, in combination with heavy ion radiation therapy to increase cell viability, inhibit necrotic apoptosis and/or reduce inflammatory response.

Description

Compound for relieving cell damage caused by heavy ion radiation, medicine and application Technical Field The invention relates to the technical field of medical biology, in particular to a compound for relieving cell damage caused by heavy ion radiation, a medicine and application. Technical Field Radiation therapy is an important tool for the treatment of malignant tumors, wherein heavy ion radiation therapy (such as carbon ion radiation therapy) is gradually popularized worldwide due to its physical and biological advantages. Compared with the traditional X-ray or proton radiotherapy, the carbon ion radiotherapy has the following characteristics that ① Bragg peak effect is achieved, and the mode of depositing energy in tissues by carbon ions enables the carbon ions to be accurately concentrated in a tumor target area, so that damage to surrounding normal tissues is reduced. ② High Linear Energy Transfer (LET) carbon ions have a higher LET value and can generate dense double strand breaks on DNA molecules, thereby causing stronger killing effect on tumor cells. ③ The hypoxia enhancement ratio is low, the killing effect of carbon ions on hypoxic cells is better than photon radiation, and the method is more suitable for treating hypoxic and radioresistant tumors. However, carbon ion radiation causes unique and serious damage to normal cells and tissues while killing tumor cells, and is mainly characterized in that 1, necrotic apoptosis (necroptosis) is induced, and the cell death mode is different from the traditional apoptosis, and the process is accompanied by cell membrane rupture and cell content release, so that severe inflammatory reaction is triggered, and 2, an inflammation related signal pathway such as NF- κB pathway is activated, so that up-regulation of pro-inflammatory factors (IL 1A, IL, B, IL6, CXCL1/2/3 and the like) is caused, so that tissue inflammation and adverse reactions can be aggravated. At present, a plurality of radioprotectors or radiosensitizers have been proposed in clinical and experimental researches, for example, 1, a free radical scavenger (such as amifostine Amifostine) is mainly used for reducing DNA damage caused by photon radiotherapy, but has limited protection effect on high LET radiation, 2, a DNA repair promoter is used for enhancing the self-repair capability of cells, but often has the problem of insufficient specificity or larger side effect, so that the existing protection means are not ideal for cell damage caused by heavy ion radiation, and especially can not effectively solve the special problem of coexistence of necrotic apoptosis and inflammatory reaction. Therefore, how to develop a drug capable of specifically relieving heavy ion radiation injury, improving cell survival and reducing inflammatory reaction is a technical problem to be solved currently. Disclosure of Invention The invention aims to provide a compound or a drug capable of relieving or preventing cell damage caused by heavy ion radiation, which can improve the cell cloning survival rate, inhibit necrotic apoptosis and weaken inflammatory reaction, thereby improving the survival ability of normal cells after heavy ion radiation. The invention adopts the following technical scheme: in a first aspect, the invention provides a compound for alleviating or preventing cell damage caused by heavy ion radiation, wherein the compound is Necrosulfonamide, and the structure of the compound is shown as formula I: In a second aspect, the present invention provides a medicament for alleviating or preventing cell damage caused by heavy ion radiation, which comprises the above compound and a pharmaceutically acceptable carrier; in a third aspect, the invention provides the use of the above compound or medicament in the manufacture of a medicament for alleviating or preventing cell damage caused by heavy ion radiation; Further, the application is selected from any one or more of alleviating or preventing cell injury, tissue inflammatory reaction and treatment related adverse reaction caused in the heavy ion radiotherapy process; Still further, the methods for alleviating or preventing cell damage during heavy ion radiation therapy are selected from improving cell viability and/or inhibiting necrotic apoptosis; still further, the reducing or preventing the inflammatory response of the tissue is to attenuate an inflammation-associated transcriptional signal; Further, the indicated uses are in combination with heavy ion radiation therapy to increase cell viability, inhibit cell necrotic apoptosis, and/or reduce inflammatory responses; compared with the prior art, the invention has the following beneficial effects: 1. The specific protection function is that under the condition of carbon ion radiation, the cloning formation rate and the viability of cells can be obviously improved, but the specific protection function is not shown under the traditional photon radiation such as X rays, and the specific application